BAY 3389934
Alternative Names: BAY-3389934Latest Information Update: 22 Sep 2025
At a glance
- Originator Bayer
- Class Anticoagulants; Small molecules
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Blood coagulation disorders
Most Recent Events
- 16 Sep 2025 Bayer plans a phase I trial for Blood coagulation disorders (In volunteers) in Japan (IV, Infusion) in September 2025 (NCT07176728)
- 08 Sep 2025 Bayer completes a phase I clinical trial in Blood coagulation disorders (unspecified route) (EUCT2022-502866-25-00) (CTIS2022-502866-25-00)
- 29 Jun 2025 Bayer suspends phase I clinical trials in Blood coagulation disorders in Belgium, France, Germany, Netherlands due to patient safety concerns (IV) (NCT06854640) (EUCT2024-515635-30-00)